BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 30015632)

  • 21. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
    Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
    Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A clinicopathological experience in acute myeloid leukemia: Effects of clinical data and status of FLT3, CEBPA and NPM1 on prognosis.
    Yener E; Ozcan K; Öngören Ş; Salihoğlu A; Demiröz AS; Akı H
    Indian J Pathol Microbiol; 2022; 65(3):642-648. PubMed ID: 35900493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. hnRNP K in PU.1-containing complexes recruited at the CD11b promoter: a distinct role in modulating granulocytic and monocytic differentiation of AML-derived cells.
    Nika E; Brugnoli F; Piazzi M; Lambertini E; Grassilli S; Bavelloni A; Piva R; Capitani S; Bertagnolo V
    Biochem J; 2014 Oct; 463(1):115-22. PubMed ID: 25005557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
    Falini B; Martelli MP; Bolli N; Sportoletti P; Liso A; Tiacci E; Haferlach T
    Blood; 2011 Jan; 117(4):1109-20. PubMed ID: 21030560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nucleophosmin mutation in de-novo acute myeloid leukemia.
    Rastogi P; Naseem S; Varma N; Varma S
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):77-85. PubMed ID: 26669619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutant NPM1-regulated lncRNA HOTAIRM1 promotes leukemia cell autophagy and proliferation by targeting EGR1 and ULK3.
    Jing Y; Jiang X; Lei L; Peng M; Ren J; Xiao Q; Tao Y; Tao Y; Huang J; Wang L; Tang Y; Yang Z; Yang Z; Zhang L
    J Exp Clin Cancer Res; 2021 Oct; 40(1):312. PubMed ID: 34615546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Up-regulation of translation eukaryotic initiation factor 4E in nucleophosmin 1 haploinsufficient cells results in changes in CCAAT enhancer-binding protein α activity: implications in myelodysplastic syndrome and acute myeloid leukemia.
    Khanna-Gupta A; Abayasekara N; Levine M; Sun H; Virgilio M; Nia N; Halene S; Sportoletti P; Jeong JY; Pandolfi PP; Berliner N
    J Biol Chem; 2012 Sep; 287(39):32728-37. PubMed ID: 22851180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Runx1 deletion or dominant inhibition reduces Cebpa transcription via conserved promoter and distal enhancer sites to favor monopoiesis over granulopoiesis.
    Guo H; Ma O; Speck NA; Friedman AD
    Blood; 2012 May; 119(19):4408-18. PubMed ID: 22451420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.
    Wen XM; Lin J; Yang J; Yao DM; Deng ZQ; Tang CY; Xiao GF; Yang L; Ma JC; Hu JB; Qian W; Qian J
    Int J Clin Exp Pathol; 2014; 7(10):6832-40. PubMed ID: 25400766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia.
    Loghavi S; DiNardo CD; Furudate K; Takahashi K; Tanaka T; Short NJ; Kadia T; Konopleva M; Kanagal-Shamanna R; Farnoud NR; Pierce S; Khoury JD; Jorgensen JL; Patel KP; Daver N; Yilmaz M; Medeiros LJ; Kantarjian H; Ravandi F; Wang SA
    Br J Haematol; 2021 Mar; 192(6):1054-1063. PubMed ID: 33618432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The human nucleophosmin 1 mutation A inhibits myeloid differentiation of leukemia cells by modulating miR-10b.
    Zou Q; Tan S; Yang Z; Wang J; Xian J; Zhang S; Jin H; Yang L; Wang L; Zhang L
    Oncotarget; 2016 Nov; 7(44):71477-71490. PubMed ID: 27669739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study.
    Miyashita N; Onozawa M; Yoshida S; Kimura H; Takahashi S; Yokoyama S; Matsukawa T; Hirabayashi S; Fujisawa S; Mori A; Ota S; Kakinoki Y; Tsutsumi Y; Yamamoto S; Miyagishima T; Nagashima T; Ibata M; Wakasa K; Haseyama Y; Fujimoto K; Ishihara T; Sakai H; Kondo T; Teshima T
    Int J Hematol; 2023 Jul; 118(1):36-46. PubMed ID: 36853451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.
    Falini B; Sportoletti P; Brunetti L; Martelli MP
    Br J Haematol; 2015 Aug; 170(3):305-22. PubMed ID: 25891481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nucleophosmin Mutants Promote Adhesion, Migration and Invasion of Human Leukemia THP-1 Cells through MMPs Up-regulation via Ras/ERK MAPK Signaling.
    Xian J; Shao H; Chen X; Zhang S; Quan J; Zou Q; Jin H; Zhang L
    Int J Biol Sci; 2016; 12(2):144-55. PubMed ID: 26884713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nucleophosmin 1: from its pathogenic role to a tantalizing therapeutic target in acute myeloid leukemia.
    Shi Y; Xue Y; Wang C; Yu L
    Hematology; 2022 Dec; 27(1):609-619. PubMed ID: 35621728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia.
    Uckelmann HJ; Haarer EL; Takeda R; Wong EM; Hatton C; Marinaccio C; Perner F; Rajput M; Antonissen NJC; Wen Y; Yang L; Brunetti L; Chen CW; Armstrong SA
    Cancer Discov; 2023 Mar; 13(3):746-765. PubMed ID: 36455613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy.
    Gu X; Hu Z; Ebrahem Q; Crabb JS; Mahfouz RZ; Radivoyevitch T; Crabb JW; Saunthararajah Y
    J Biol Chem; 2014 May; 289(21):14881-95. PubMed ID: 24695740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.
    Russ AC; Sander S; Lück SC; Lang KM; Bauer M; Rücker FG; Kestler HA; Schlenk RF; Döhner H; Holzmann K; Döhner K; Bullinger L
    Haematologica; 2011 Dec; 96(12):1783-91. PubMed ID: 21880628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytoplasmic Expression of TP53INP2 Modulated by Demethylase FTO and Mutant NPM1 Promotes Autophagy in Leukemia Cells.
    Huang J; Sun M; Tao Y; Ren J; Peng M; Jing Y; Xiao Q; Yang J; Lin C; Lei L; Yang Z; Zhang L
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.